Skip to content

Study · Observational study · n = 39 · 2023

8 results

Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational "Real-Life" Study.

Merlo FD, Aimasso U, Ossola M, Ippolito M, Cravero L, Ponzo V, Bo S

Nutrients14 Jun 2023Cited by 11 (Europe PMC)

PMID37375644 (opens in a new tab)PMCIDPMC10305110 (opens in a new tab)DOI10.3390/nu15122740 (opens in a new tab)PepBankPUB-37375644
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Liraglutide, a glucagon-like peptide-1 agonist, has been shown to have beneficial effects on fecal output in short bowel syndrome (SBS) by small human studies. Its potential effects early after gut resection are not known. In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection. Stomal/fecal and urinary outcomes, serum/urinary electrolytes, and body composition were assessed. Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated. The main liraglutide-related side effect was mild nausea, except in one patient, who experienced severe nausea/vomiting. The median ostomy/fecal output was significantly reduced by -550 mL/day after 6 months of treatment (vs. -200 mL/day in untreated, p = 0.04). The number of patients reaching a ≥20% output reduction was 10/19 (52.6%) treated vs. 3/20 (15.0%) untreated patients (p = 0.013) at 1 month and 12/19 (63.2%) vs. 6/20 (30.0%) (p = 0.038) at 6 months, respectively. Participants with a clinically relevant output reduction at 6 months had a significantly lower baseline weight and BMI. Energy parenteral supply significantly decreased, while infused volumes, oral energy, and fluid intakes slightly decreased, though not significantly. This pilot study supports liraglutide benefits in ostomy/fecal output early after surgical gut resection in SBS patients, particularly in those with lower baseline weight values.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome, median ostomy or fecal output fell by 550 mL/day after 6 months of liraglutide, versus 200 mL/day in untreated patients (p = 0.04).

    In plain wordsIn adults with short bowel syndrome, stool or stoma output fell more with liraglutide than in untreated patients after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseOstomy or fecal output at 6 months
    Study

    n = 39

    Comparator
    Untreated SBS patients
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Median change in output
    −550 mL/day
    liraglutide, 6 months
    Median change in output
    −200 mL/day
    untreated

    Source sentences

    Summary
    The median ostomy/fecal output was significantly reduced by -550 mL/day after 6 months of treatment (vs. -200 mL/day in untreated, p = 0.04).
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  2. 02HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome, 52.6% of patients on liraglutide reached a 20% or greater output reduction at 1 month, versus 15.0% of untreated patients (p = 0.013).

    In plain wordsIn adults with short bowel syndrome, more patients on liraglutide than untreated patients cut their output by at least 20% at 1 month.

    Peptide
    Liraglutide
    Outcome
    IncreaseOutput reduction of 20% or more at 1 month
    Study

    n = 39

    Comparator
    Untreated SBS patients
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · 1 monthAs given in this study (human).

    Measurements

    Proportion with 20% or greater output reduction
    52.6%
    liraglutide, 1 month
    Proportion with 20% or greater output reduction
    15%
    untreated, 1 month

    Source sentences

    Summary
    The number of patients reaching a ≥20% output reduction was 10/19 (52.6%) treated vs. 3/20 (15.0%) untreated patients (p = 0.013
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  3. 03HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome, 63.2% of patients on liraglutide reached a 20% or greater output reduction at 6 months, versus 30.0% of untreated patients (p = 0.038).

    In plain wordsIn adults with short bowel syndrome, more patients on liraglutide than untreated patients cut their output by at least 20% at 6 months.

    Peptide
    Liraglutide
    Outcome
    IncreaseOutput reduction of 20% or more at 6 months
    Study

    n = 39

    Comparator
    Untreated SBS patients
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Proportion with 20% or greater output reduction
    63.2%
    liraglutide, 6 months
    Proportion with 20% or greater output reduction
    30%
    untreated, 6 months

    Source sentences

    Summary
    12/19 (63.2%) vs. 6/20 (30.0%) (p = 0.038
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  4. 04HumanObservational studySafety outcome

    In adults with short bowel syndrome, the main liraglutide-related side effect was mild nausea.

    In plain wordsIn adults with short bowel syndrome, the main side effect of liraglutide was mild nausea.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea
    Study

    n = 19

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The main liraglutide-related side effect was mild nausea
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  5. 05HumanObservational studySafety outcome

    In adults with short bowel syndrome, one patient on liraglutide had severe nausea or vomiting.

    In plain wordsIn adults with short bowel syndrome, one patient on liraglutide had severe nausea or vomiting.

    Peptide
    Liraglutide
    Outcome
    Not applicableSevere nausea or vomiting
    Study

    n = 19

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    except in one patient, who experienced severe nausea/vomiting.
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  6. 06HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome on liraglutide, patients with a clinically relevant output reduction at 6 months had significantly lower baseline weight and BMI.

    In plain wordsIn adults with short bowel syndrome on liraglutide, those whose output fell clearly had lower starting weight and BMI.

    Peptide
    Liraglutide
    Outcome
    DecreaseBaseline weight and BMI in output responders
    Study

    n = 19

    Outcome group
    Body weight · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Participants with a clinically relevant output reduction at 6 months had a significantly lower baseline weight and BMI.
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  7. 07HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome, energy supplied by parenteral nutrition decreased significantly.

    In plain wordsIn adults with short bowel syndrome, the energy given by intravenous nutrition fell significantly.

    Peptide
    Liraglutide
    Outcome
    DecreaseParenteral energy supply
    Study

    n = 19

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Energy parenteral supply significantly decreased
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.
  8. 08HumanObservational studyEfficacy outcome

    In adults with short bowel syndrome, infused volumes, oral energy and fluid intakes decreased slightly, though not significantly.

    In plain wordsIn adults with short bowel syndrome, infused volumes and oral energy and fluid intakes fell slightly, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeInfused volumes, oral energy and fluid intake
    Study

    n = 19

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while infused volumes, oral energy, and fluid intakes slightly decreased, though not significantly.
    2 context sentences
    Summary · context
    In this pilot observational study, we described the 1- and 6-month liraglutide effects in 19 adult patients with a new SBS diagnosis within 1 month after surgical resection.
    Summary · context
    Both within-group differences and between-group comparisons with 20 SBS patients refusing liraglutide treatment were evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.